Ghana vs South Sudan: Tuberculosis patients who tested positive for HIV
Ghana
1,820 patients
in 2021
South Sudan
2,090 patients
in 2021
Ghana rank
31st
South Sudan rank
28th
Tuberculosis patients who tested positive for HIV over time
- Ghana
- South Sudan
How they compare
South Sudan currently reports 2,090 patients against 1,820 patients in Ghana, a difference of 270 patients.
That makes South Sudan's figure about 1.1 times Ghana's.
The two have swapped places 1 time across 11 shared years of data; in 2011 it was Ghana ahead.
Ghana ranks 31st and South Sudan ranks 28th of 201 countries.
Ghana has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Ghana | South Sudan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,745 patients | 998 patients | 1,747 patients | Ghana |
| 2020s | 1,969 patients | 1,896 patients | 72.5 patients | Ghana |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis patients who tested positive for hiv, Ghana or South Sudan?
- South Sudan, at 2,090 patients against 1,820 patients in Ghana as of 2021.
- What is the difference in tuberculosis patients who tested positive for hiv between Ghana and South Sudan?
- 270 patients, with South Sudan ahead.
- How many years of comparable data are there for Ghana and South Sudan?
- 11 years are reported by both, from 2011 to 2021.
- How do Ghana and South Sudan rank globally for tuberculosis patients who tested positive for hiv?
- Ghana ranks 31st and South Sudan ranks 28th of 201 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026); Population based on various sources (2024) – with minor processing by Our World in Data, published as Tuberculosis patients who tested positive for HIV. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of tuberculosis (new and relapsed) patients that tested positive for HIV.